125 related articles for article (PubMed ID: 17916757)
1. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
De Melo VA; Milojkovic D; Khorashad JS; Marin D; Goldman JM; Apperley JF; Reid AG
Blood; 2007 Oct; 110(8):3086-7. PubMed ID: 17916757
[No Abstract] [Full Text] [Related]
2. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Fabarius A; Haferlach C; Müller MC; Erben P; Lahaye T; Giehl M; Frank O; Seifarth W; Hehlmann R; Hochhaus A
Haematologica; 2007 Jun; 92(6):834-7. PubMed ID: 17550857
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
[No Abstract] [Full Text] [Related]
5. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.
Nagao T; Takahashi N; Kameoka Y; Noguchi S; Shinohara Y; Ohyagi H; Kume M; Sawada K
Intern Med; 2013; 52(22):2567-71. PubMed ID: 24240798
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
8. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Baldazzi C; Luatti S; Marzocchi G; Stacchini M; Gamberini C; Castagnetti F; Palandri F; Rosti G; Baccarani M; Testoni N
Leuk Res; 2009 Dec; 33(12):e218-20. PubMed ID: 19525008
[No Abstract] [Full Text] [Related]
9. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Ali S; Sergeant R; O'Brien SG; Foroni L; Hedgley C; Gerrard G; Milojkovic D; Stringaris K; Khoder A; Alsuliman A; Gilleece M; Gabriel IH; Cooper N; Goldman JM; Apperley JF; Clark RE; Marin D; Rezvani K
Blood; 2012 Jul; 120(3):697-8. PubMed ID: 22822001
[No Abstract] [Full Text] [Related]
10. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
11. Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.
Bacher U; Hochhaus A; Berger U; Hiddemann W; Hehlmann R; Haferlach T; Schoch C
Leukemia; 2005 Mar; 19(3):460-3. PubMed ID: 15625554
[No Abstract] [Full Text] [Related]
12. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib.
Shah NP
Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
[TBL] [Abstract][Full Text] [Related]
14. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.
Abdelhalim A; Barcos M; Block AW; Sait SN; Starostik P; Wetzler M; Wang ES
Leuk Lymphoma; 2007 May; 48(5):1053-6. PubMed ID: 17487757
[No Abstract] [Full Text] [Related]
15. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
16. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Jabbour E; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
[TBL] [Abstract][Full Text] [Related]
17. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
[No Abstract] [Full Text] [Related]
18. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
20. Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.
Paquette RL; Nicoll J; Chalukya M; Gondek L; Jasek M; Sawyers CL; Shah NP; Maciejewski J
Leuk Res; 2010 Jun; 34(6):708-13. PubMed ID: 19804904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]